A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release
A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release
复制标题
DOI：
10.1016/j.drugalcdep.2017.11.023
复制
发表时间：
2018-03-01
影响因子：
4.2
通讯作者：
Rich, Josiah
中科院分区：
文献类型：
--
作者：
Brinkley-Rubinstein, Lauren;McKenzie, Michelle;Rich, Josiah
最近，被监禁者阿片类药物过量的风险增加。美沙酮维持治疗（MMT）是解决阿片类药物使用障碍和防止过量用药的有效方法；然而，美国很少有看守所和监狱对被监禁的人实行 MMT 监禁或继续监禁。在当前的研究中，评估了一项随机对照试验的 12 个月结果，在该试验中，个人在罗德岛惩教署 (RIDOC) 被监禁期间接受了 MMT。一项治疗分析包括总共 179 名参与者，其中 128 名参与者在出院前一天服用了美沙酮，51 名没有服用美沙酮。这项研究的结果表明，出狱后 12 个月，在监禁期间继续接受 MMT 的个人报告在过去 30 天内吸食海洛因和注射吸毒的可能性较小。此外，与出院前未立即接受美沙酮的人相比，他们报告的非致命性用药过量较少，并且更有可能在 12 个月的随访期内持续接受治疗。这些研究结果表明，为被监禁者提供持续的 MMT 服务对释放后许多与阿片类药物相关的结果具有持续、长期的影响。
Recently, incarcerated individuals are at increased risk of opioid overdose. Methadone maintenance treatment (MMT) is an effective way to address opioid use disorder and prevent overdose; however, few jails and prisons in the United States initiate or continue people who are incarcerated on MMT. In the current study, the 12 month outcomes of a randomized control trial in which individuals were provided MMT while incarcerated at the Rhode Island Department of Corrections (RIDOC) are assessed. An as-treated analysis included a total of 179 participants-128 who were, and 51 who were not, dosed with methadone the day before they were released from the RIDOC. The results of this study demonstrate that 12 months post-release individuals who received continued access to MMT while incarcerated were less likely to report using heroin and engaging in injection drug use in the past 30 days. In addition, they reported fewer non-fatal overdoses and were more likely to be continuously engaged in treatment in the 12-month follow-up period compared to individuals who were not receiving methadone immediately prior to release. These findings indicate that providing incarcerated individuals continued access to MMT has a sustained, long-term impact on many opioid-related outcomes post release.